JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AMED
2501
PUT
DELISTED
Amedisys
AMED
| $11.6M | ﹤0.01% |
+128,000
| New | +$11.8M |
2024 Q4
0 quarters
|
|
2502
PGIM Active High Yield Bond ETF
PHYL
$1.4B
| $11.6M | ﹤0.01% |
+333,942
| New | +$11.8M |
2024 Q4
0 quarters
|
|
2503
iShares Morningstar US Equity ETF
ILCB
$1.31B
| $11.6M | ﹤0.01% |
142,825
+3,868
| +3% | +$316K |
2013 Q2
46 quarters
|
|
2504
Harmony Gold Mining
HMY
$10.9B
| $11.5M | ﹤0.01% |
1,406,125
+827,946
| +143% | +$8.04M |
2020 Q4
16 quarters
|
|
2505
PUT
Royal Caribbean
RCL
$74.3B
| $11.5M | ﹤0.01% |
50,000
+10,600
| +27% | +$2.35M |
2024 Q2
2 quarters
|
|
2506
iShares Russell Top 200 Growth ETF
IWY
$16.4B
| $11.5M | ﹤0.01% |
49,003
+4,593
| +10% | +$1.05M |
2019 Q3
21 quarters
|
|
2507
TG Therapeutics
TGTX
$8.31B
| $11.5M | ﹤0.01% |
382,959
-337,839
| -47% | -$9.7M |
2016 Q4
32 quarters
|
|
2508
JPMorgan BetaBuilders US Treasury Bond 3-10 Year ETF
BBIB
$52.4M
| $11.5M | ﹤0.01% |
119,686
+109,412
| +1,065% | +$10.7M |
2024 Q3
1 quarter
|
|
2509
CALL
Deutsche Bank
DB
$65.7B
| $11.5M | ﹤0.01% |
675,000
-2,025,300
| -75% | -$34.8M |
2022 Q1
11 quarters
|
|
2510
SoFi Technologies
SOFI
$20.4B
| $11.5M | ﹤0.01% |
745,856
-6,726,519
| -90% | -$87.4M |
2021 Q1
15 quarters
|
|
2511
Vanguard S&P Small-Cap 600 ETF
VIOO
$4.07B
| $11.5M | ﹤0.01% |
108,219
+25,301
| +31% | +$2.8M |
2017 Q4
28 quarters
|
|
2512
JPMorgan US Value Factor ETF
JVAL
$995M
| $11.5M | ﹤0.01% |
265,189
+9,493
| +4% | +$419K |
2022 Q4
8 quarters
|
|
2513
Hamilton Insurance Group
HG
$3.37B
| $11.4M | ﹤0.01% |
600,646
-261,668
| -30% | -$4.84M |
2024 Q1
3 quarters
|
|
2514
CALL
Zoom
ZM
$27.1B
| $11.4M | ﹤0.01% |
140,000
| – | – |
2024 Q3
1 quarter
|
|
2515
First Trust Managed Municipal ETF
FMB
$1.94B
| $11.4M | ﹤0.01% |
223,654
-197,756
| -47% | -$10.2M |
2023 Q2
6 quarters
|
|
2516
Transocean
RIG
$5.77B
| $11.4M | ﹤0.01% |
3,041,897
+2,287,191
| +303% | +$9.5M |
2013 Q2
46 quarters
|
|
2517
Stepan Co
SCL
$1.43B
| $11.4M | ﹤0.01% |
176,066
+33,276
| +23% | +$2.46M |
2013 Q2
46 quarters
|
|
|
JBGS
2518
JBG SMITH
JBGS
$619M
| $11.4M | ﹤0.01% |
741,071
+82,779
| +13% | +$1.39M |
2017 Q3
29 quarters
|
|
2519
CRISPR Therapeutics
CRSP
$5.36B
| $11.4M | ﹤0.01% |
289,177
-65,065
| -18% | -$3.07M |
2018 Q2
26 quarters
|
|
2520
CALL
Wayfair
W
$13.9B
| $11.4M | ﹤0.01% |
256,800
-7,100
| -3% | -$335K |
2020 Q4
16 quarters
|
|
2521
Avantis US Large Cap Value ETF
AVLV
$21.4B
| $11.4M | ﹤0.01% |
170,256
-23,110
| -12% | -$1.57M |
2023 Q2
6 quarters
|
|
2522
PUT
Tenet Healthcare
THC
$20.8B
| $11.4M | ﹤0.01% |
90,000
+4,500
| +5% | +$669K |
2024 Q3
1 quarter
|
|
2523
CALL
Monster Beverage
MNST
$84.1B
| $11.3M | ﹤0.01% |
431,400
+23,000
| +6% | +$610K |
2021 Q3
13 quarters
|
|
2524
Orion
OEC
$327M
| $11.3M | ﹤0.01% |
717,377
+110,911
| +18% | +$1.87M |
2016 Q1
35 quarters
|
|
2525
Four Corners Property Trust
FCPT
$2.37B
| $11.3M | ﹤0.01% |
417,304
+24,856
| +6% | +$709K |
2015 Q4
36 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.